keyword
MENU ▼
Read by QxMD icon Read
search

"peptide receptor radionuclide therapy"

keyword
https://www.readbyqxmd.com/read/29930736/somatostatin-receptor-type-2-as-a-radiotheranostic-pet-reporter-gene-for-oncologic-interventions
#1
Pedram Heidari, Anchisa Kunawudhi, Jordi Martinez-Quintanilla, Alicia Szretter, Khalid Shah, Umar Mahmood
Reporter gene systems can serve as therapy targets. However, the therapeutic use of reporters has been limited by the challenges of transgene delivery to a majority of cancer cells. This study specifically assesses the efficacy of targeting human somatostatin receptor subtype 2 (hSSTR2) with peptide receptor radionuclide therapy (PRRT) when a small subpopulation of cells bears the transgene. Methods: The hSSTR2 transgene was delivered to A549 and Panc-1tumors using the lentiviral vector, LV-hSSTR2-IRES-GFP or murine mesenchymal stem cells (mMSC)s using a retroviral vector...
2018: Theranostics
https://www.readbyqxmd.com/read/29916115/reducing-the-number-of-cts-performed-to-monitor-personalized-dosimetry-during-peptide-receptor-radionuclide-therapy-prrt
#2
Alexandre Chicheportiche, Faozi Artoul, Arnon Schwartz, Simona Grozinsky-Glasberg, Amichay Meirovitz, David J Gross, Jeremy Godefroy
BACKGROUND: Peptide receptor radionuclide therapy (PRRT) with [177 Lu]-DOTA-TATE is an effective treatment of neuroendocrine tumors (NETs). After each cycle of treatment, patient dosimetry evaluates the radiation dose to the risk organs, kidneys, and bone marrow, the most radiosensitive tissues. Absorbed doses are calculated from the radioactivity in the blood and from single photon emission computed tomography (SPECT) images corrected by computed tomography (CT) acquired after each course of treatment...
June 19, 2018: EJNMMI Physics
https://www.readbyqxmd.com/read/29912750/177lu-dotatate-therapy-in-patients-with-neuroendocrine-tumours-including-high-grade-who-g3-neuroendocrine-tumours-response-to-treatment-and-long-term-survival-update
#3
Emre Demirci, Levent Kabasakal, Turkay Toklu, Meltem Ocak, Onur E Şahin, Nalan Alan-Selcuk, Ahmet Araman
PURPOSE: Upon diagnosis, distant metastases are encountered in 21-50% of neuroendocrine tumours (NETs). However, few systemic treatment options are available for the well-differentiated NETs in the metastatic stage. Lu-DOTATATE is one of the most effective treatments in this limited patient group. We retrospectively investigated its efficacy and effect on the survival in patients with both well-differentiated and grade III NETs who had high uptake in pretherapeutic Ga-DOTATATE PET/computed tomography scans...
June 15, 2018: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/29905961/treatment-planning-algorithm-for-prrt-considering-multiple-tumor-lesions-and-organs-at-risk
#4
Luis David Jiménez-Franco, Peter Kletting, Ambros J Beer, Gerhard Glatting
PURPOSE: Peptide receptor radionuclide therapy (PRRT) has shown promising results in the treatment of tumors with high expression of somatostatin receptors such as neuroendocrine tumors (NETs) and meningioma. However, PRRT potentially produces high renal and red marrow (RM) toxicity, the kidneys usually being the dose-limiting organ. Previously, it was shown that an improved therapeutic index can be achieved by choosing an optimal combination of injected activity and peptide molar amount...
June 15, 2018: Medical Physics
https://www.readbyqxmd.com/read/29902988/additional-hepatic-166-ho-radioembolization-in-patients-with-neuroendocrine-tumours-treated-with-177-lu-dotatate-a-single-center-interventional-non-randomized-non-comparative-open-label-phase-ii-study-hepar-plus-trial
#5
Arthur J A T Braat, Dik J Kwekkeboom, Boen L R Kam, Jaap J M Teunissen, Wouter W de Herder, Koen M A Dreijerink, Rob van Rooij, Gerard C Krijger, Hugo W A M de Jong, Maurice A A J van den Bosch, Marnix G E H Lam
BACKGROUND: Neuroendocrine tumours (NET) consist of a heterogeneous group of neoplasms with various organs of origin. At diagnosis 21% of the patients with a Grade 1 NET and 30% with a Grade 2 NET have distant metastases. Treatment with peptide receptor radionuclide therapy (PRRT) shows a high objective response rate and long median survival after treatment. However, complete remission is almost never achieved. The liver is the most commonly affected organ in metastatic disease and is the most incriminating factor for patient survival...
June 15, 2018: BMC Gastroenterology
https://www.readbyqxmd.com/read/29872498/potentiation-of-177-lu-octreotate-peptide-receptor-radionuclide-therapy-of-human-neuroendocrine-tumor-cells-by-parp-inhibitor
#6
Nupur K Purohit, Rashmi G Shah, Samuel Adant, Michael Hoepfner, Girish M Shah, Jean-Mathieu Beauregard
For patients with inoperable neuroendocrine tumors (NETs) expressing somatostatin receptors, peptide receptor radionuclide therapy (PRRT) with 177 Lu-[DOTA0-Tyr3]-octreotate (177 Lu-octreotate) is one of the most promising targeted therapeutic options but it rarely achieves cure. Therefore, different approaches are being tested to increase the efficacy of 177 Lu-octreotate PRRT in NET patients. Using the gastroenteropancreatic BON-1 and the bronchopulmonary NCI-H727 as NET cell models, here we report that pharmacological inhibitors of DNA repair-associated enzyme poly(ADP-ribose) polymerase-1 (PARPi) potentiate the cytotoxic effect of 177 Lu-octreotate on 2D monolayer and 3D spheroid models of these two types of NET cells...
May 15, 2018: Oncotarget
https://www.readbyqxmd.com/read/29862235/advances-on-systemic-treatment-for-lung-neuroendocrine-neoplasms
#7
REVIEW
Nikolaos Tsoukalas, Panagiotis Baxevanos, Eleni Aravantinou-Fatorou, Maria Tolia, Michail Galanopoulos, Konstantinos Tsapakidis, George Kyrgias, Christos Toumpanakis, Gregory Kaltsas
Lung well-to-moderately differentiated neuroendocrine tumors (also known as carcinoids) and large cell neuroendocrine lung carcinoma (poorly differentiated neuroendocrine tumor) are rare neuroendocrine neoplasms, which account for less than 4% of all lung neoplasms. Due to their low incidence, their systemic treatment is greatly influenced by therapeutic evidence derived from the more frequent gastroenteropancreatic neuroendocrine neoplasms and/or small cell lung carcinoma leading to significant bias. Currently, employed systemic therapies for lung carcinoids, aiming at controlling tumor growth include long acting somatostatin analogues (SSAs), peptide receptor radionuclide therapy, chemotherapy and molecular-targeted therapy...
April 2018: Annals of Translational Medicine
https://www.readbyqxmd.com/read/29785514/correlation-of-dose-with-toxicity-and-tumour-response-to-90-y-and-177-lu-prrt-provides-the-basis-for-optimization-through-individualized-treatment-planning
#8
REVIEW
Marta Cremonesi, Mahila Esmeralda Ferrari, Lisa Bodei, Carlo Chiesa, Anna Sarnelli, Cristina Garibaldi, Massimiliano Pacilio, Lidia Strigari, Paul Eugene Summers, Roberto Orecchia, Chiara Maria Grana, Francesca Botta
PURPOSE: Peptide receptor radionuclide therapy (PRRT) with 90 Y-labelled and 177 Lu-labelled peptides is an effective strategy for the treatment of metastatic/nonresectable neuroendocrine tumours (NETs). Dosimetry provides important information useful for optimizing PRRT with individualized regimens to reduce toxicity and increase tumour responses. However, this strategy is not applied in routine clinical practice, despite the fact that several dosimetric studies have demonstrated significant dose-effect correlations for normal organ toxicity and tumour response that can better guide therapy planning...
May 21, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29762236/acute-pancreatitis-following-peptide-receptor-radionuclide-therapy-an-unusual-adverse-event
#9
Ioannis Karfis, Gwennaëlle Marin, Godelieve Machiels, Alain Hendlisz, Patrick Flamen
A 54-year-old man with grade 2 rectal neuroendocrine tumor and hepatic, pancreatic, and bone metastases was treated with Lu-DOTATATE as second-line therapy, after failure of somatostatin analogues. Two weeks after the first injection, he presented at the emergency department with acute pancreatitis. We hypothesized that this unusual adverse event, never been reported so far, was the result of acute tumor irradiation after PRRT, leading to peritumoral inflammation and edema with obstruction of an accessory pancreatic duct...
May 14, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29742602/impressive-response-to-tandem-treatment-with-90y-dotatoc-and-177lu-dotatoc-in-grade-3-pancreatic-neuroendocrine-carcinoma
#10
Alice Lorenzoni, Antonella Capozza, Salvatore Artale, Marco Maccauro, Ettore Cesare Seregni
Peptide receptor radionuclide therapy is an effective, well-tolerated, treatment for well-differentiated neuroendocrine tumors, resulting in a significant survival benefit and improvement of quality of life. Very few data are available on peptide receptor radionuclide therapy effectiveness in grade 3 neuroendocrine carcinomas with high somatostatin receptor expression. We report the case of a 70-year-old woman with metastatic pancreatic grade 3 neuroendocrine carcinoma who underwent 6 cycles of tandem treatment with investigational radiopharmaceuticals Y-DOTATOC and Lu-DOTATOC achieving an impressive response...
May 7, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29741203/peptide-receptor-radionuclide-therapy-for-advanced-gastroenteropancreatic-neuroendocrine-tumors-from-oncology-perspective
#11
Agnieszka Kolasińska-Ćwikła, Anna Łowczak, Katarzyna Maciejkiewicz Maciejkiewicz, Jarosław Bogdan Ćwikła
Peptide Receptor Radionuclide Therapy (PRRT) is a form of molecular targeted therapy which is performed by using a small peptide (somatostatin analogue - SSA) that is coupled with a radionuclide beta emitting radiation. PRRT is a nuclear medicine for the systemic treatment of non-resectable, metastasized well/moderately differentiated, neuroendocrine tumours (NET) with overexpression of somatostatin receptor. These types of tumours include gastroenteropancreatic neoplasm (GEP-NENs), e.g. arising from the small bowel (often called carcinoid tumours), the pancreas, duodenum or stomach, but also from the large bowel or the lung and many other tissues (so called diffuse neuroendocrine system)...
2018: Nuclear Medicine Review. Central & Eastern Europe
https://www.readbyqxmd.com/read/29719482/first-results-and-experience-with-prrt-in-south-africa
#12
Mariza Vorster, M R Modiselle, C S Corbett, I O Lawal, John R Buscombe, Mike M Sathekge
Neuroendocrine tumors (NETs) are a diverse group of tumors that often present late due to nonspecific symptoms. These tumors frequently express somatostatin receptors (SSRs), which allows for positron emission tomography/computed tomography (PET/CT) imaging with Ga-68-DOTATATE. In eligible patients, this may then be followed by peptide receptor radionuclide therapy (PRRT). Here, we report our initial results and experience with PRRT in a developing country, as one of the first groups to provide this therapy in South Africa...
April 2018: World Journal of Nuclear Medicine
https://www.readbyqxmd.com/read/29688946/lung-metastases-of-intracranial-atypical-meningioma-diagnosed-on-posttherapeutic-imaging-after-177lu-dotatate-therapy
#13
Philipp Backhaus, Sebastian Huss, Volkan Kösek, Matthias Weckesser, Kambiz Rahbar
Meningiomas are typically benign solitary intracranial tumors. Atypical (World Health Organization [WHO] grade II) or malignant/anaplastic (WHO grade III) meningiomas are seldom, and distant metastases occur only in rare exceptions. We present a case of a 54-year-old male patient with atypical (WHO grade II) meningioma who underwent 1 cycle of peptide receptor radionuclide therapy. Previous imaging studies were confined to the head, but posttherapeutic whole-body Lu-DOTATATE scintigraphy revealed thoracic uptake arising from previously undetected pulmonic meningioma metastases...
June 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29682195/results-and-adverse-events-of-personalized-peptide-receptor-radionuclide-therapy-with-90-yttrium-and-177-lutetium-in-1048-patients-with-neuroendocrine-neoplasms
#14
Richard P Baum, Harshad R Kulkarni, Aviral Singh, Daniel Kaemmerer, Dirk Mueller, Vikas Prasad, Merten Hommann, Franz C Robiller, Karin Niepsch, Holger Franz, Arthur Jochems, Philippe Lambin, Dieter Hörsch
Introduction: Peptide receptor radionuclide therapy (PRRT) of patients with somatostatin receptor expressing neuroendocrine neoplasms has shown promising results in clinical trials and a recently published phase III study. Methods: In our center, 2294 patients were screened between 2004 and 2014 by 68 Ga somatostatin receptor (SSTR) PET/CT. Intention to treat analysis included 1048 patients, who received at least one cycle of 90 Yttrium or 177 Lutetium-based PRRT...
March 30, 2018: Oncotarget
https://www.readbyqxmd.com/read/29681888/octreotide-does-not-inhibit-proliferation-in-five-neuroendocrine-tumor-cell-lines
#15
Samantha Exner, Vikas Prasad, Bertram Wiedenmann, Carsten Grötzinger
Somatostatin analogs (SSA) are well-established antisecretory drugs in functionally active neuroendocrine tumors (NET). Two placebo-controlled trials have recently demonstrated significant improvement of progression-free survival under SSA treatment. Furthermore, somatostatin receptor (SSTR) overexpression in NET has also been utilized for diagnostic imaging and peptide receptor radionuclide therapy (PRRT). However, PRRT in NET is associated mostly with partial and minor remission, while other radionuclide therapies reach complete remissions in up to 75% of cases...
2018: Frontiers in Endocrinology
https://www.readbyqxmd.com/read/29675259/successful-neoadjuvant-peptide-receptor-radionuclide-therapy-for-an-inoperable-pancreatic-neuroendocrine-tumour
#16
Tiago Nunes da Silva, M L F van Velthuysen, Casper H J van Eijck, Jaap J Teunissen, J Hofland, Wouter W de Herder
Non-functional pancreatic neuroendocrine tumours (NETs) can present with advanced local or distant (metastatic) disease limiting the possibility of surgical cure. Several treatment options have been used in experimental neoadjuvant settings to improve the outcomes in such cases. Peptide receptor radionuclide therapy (PPRT) using beta emitting radiolabelled somatostatin analogues has been used in progressive pancreatic NETs. We report a 55-year-old female patient with a 12.8 cm pancreatic NET with significant local stomach and superior mesenteric vein compression and liver metastases...
2018: Endocrinology, Diabetes & Metabolism Case Reports
https://www.readbyqxmd.com/read/29629319/liver-transplantation-for-unresectable-pancreatic-neuroendocrine-tumors-with-liver-metastases-in-an-era-of-transplant-oncology
#17
REVIEW
Keita Shimata, Yasuhiko Sugawara, Taizo Hibi
Patients with pancreatic neuroendocrine tumors (pNETs) very often present with a metastatic disease at the first diagnosis. Liver transplantation (LT) for unresectable pNET with liver metastases (pNETLM) has been described to prolong survival in highly selected patients, although outcomes were worse than those of patients who underwent LT for gastrointestinal NETLM (GI-NETLM). In this review, several proposed criteria are described with their rationale and controversies. Most of the data used to establish these criteria do not reflect the recent improvements of non-surgical treatments that has changed the landscape of treatment for pNETs, including the development of peptide receptor radionuclide therapy and molecular-targeted agents (sunitinib and everolimus)...
February 2018: Gland Surgery
https://www.readbyqxmd.com/read/29602040/prevention-and-management-of-carcinoid-crises-in-patients-with-high-risk-neuroendocrine-tumours-undergoing-peptide-receptor-radionuclide-therapy-prrt-literature-review-and-case-series-from-two-australian-tertiary-medical-institutions
#18
REVIEW
Gonzalo Tapia Rico, Minmin Li, Nick Pavlakis, Gabrielle Cehic, Timothy J Price
Peptide receptor radionuclide therapy (PRRT) is an important therapeutic option for somatostatin receptor (SSTR) positive metastatic and/or inoperable neuroendocrine tumours (NETs). However, in patients with poorly controlled carcinoid syndrome, it may lead to an acute flare of carcinoid symptoms or even carcinoid crisis. We report seven patients who received PRRT with (177 Lu-DOTA0 , Tyr3 ) octreotate (177 Lu-octreotate-LuTate) across two Australian tertiary medical institutions who developed acute flare of carcinoid symptoms/carcinoid crisis during/after PRRT...
May 2018: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29572257/sstr-rads-version-1-0-as-a-reporting-system-for-sstr-pet-imaging-and-selection-of-potential-prrt-candidates-a-proposed-standardization-framework
#19
Rudolf A Werner, Lilja Solnes, Mehrbod Javadi, Alexander Weich, Michael Gorin, Kenneth Pienta, Takahiro Higuchi, Andreas K Buck, Martin G Pomper, Steven P Rowe, Constantin Lapa
Reliable standards and criteria for somatostatin receptor (SSTR) positron emission tomography (PET) are still lacking. We herein propose a structured reporting system on a 5-point scale for SSTR-PET imaging, titled SSTR-RADS version 1.0, which might serve as a standardized assessment for both diagnosis and treatment planning in neuroendocrine tumors (NET). SSTR-RADS could guide the imaging specialist in interpreting SSTR-PET scans, facilitate communication with the referring clinician so that appropriate work-up for equivocal findings is pursued, and serve as a reliable tool for patient selection for planned Peptide Receptor Radionuclide Therapy...
March 23, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29554305/neuroradiological-and-neuropathological-changes-after-177lu-octreotate-peptide-receptor-radionuclide-therapy-of-refractory-esthesioneuroblastoma
#20
Julia R Schneider, Deborah R Shatzkes, Stephen C Scharf, Tristan M Tham, Kay O Kulason, François-Alexandre Buteau, Michela Del Prete, Shamik Chakraborty, Todd A Anderson, Saeed Asiry, Jean-Mathieu Beauregard, David J Langer, Peter D Costantino, John A Boockvar
BACKGROUND AND IMPORTANCE: Olfactory neuroblastoma, also known as esthesioneuroblastoma (ENB), is a malignant neoplasm with an unpredictable behavior. Currently, the widely accepted treatment is inductive chemotherapy, with or without surgery, followed by radiotherapy. Since data on genetics and molecular alterations of ENB are lacking, there is no standard molecularly targeted therapy. However, ENB commonly expresses the somatostatin receptor (SSTR) that is also expressed by neuroendocrine tumors...
March 14, 2018: Operative Neurosurgery (Hagerstown, Md.)
keyword
keyword
108898
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"